Cholangiocarcinoma clinical trials

Explore recruiting cholangiocarcinoma clinical trials.

Recruiting cholangiocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cholangiocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Neoadjuvant gemcitabine and cisplatin in combination with perioperative pembrolizumab versus upfront surgery for patients with primary resectable and borderline resectable perihilar and distal cholangiocarcinoma (NEODISCO): A Multicentre Phase 2B/3 Randomised Controlled Trial

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Spain, Italy, Portugal, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Cholangiocarcinoma treatment with radiofrequency ablation or photodynamic therapy

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine in the neoadjuvant setting of Operable intrahepatic CHOlangiocarcinoma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Germany, Belgium, Italy, Spain, Netherlands, Sweden +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study and cost-effectivity analysis.

Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cholangiocarcinoma trials by city

Cholangiocarcinoma in Toronto Cholangiocarcinoma in Vancouver Cholangiocarcinoma in Montreal Cholangiocarcinoma in Calgary Cholangiocarcinoma in Edmonton Cholangiocarcinoma in Ottawa Cholangiocarcinoma in Winnipeg Cholangiocarcinoma in Quebec City Cholangiocarcinoma in Hamilton Cholangiocarcinoma in Kitchener Cholangiocarcinoma in London Cholangiocarcinoma in Halifax Cholangiocarcinoma in New York Cholangiocarcinoma in Los Angeles Cholangiocarcinoma in Chicago Cholangiocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease